CCL18 as immunomarker in patients with lung carcinoma

In current study fifty two patients suffering from lung cancer disease were admitted to the Oncology Unit of Al-Sadder Medical City /Al-Najaf Al-Ashraf during the period from January till August 2014. All lung cancer patients were diagnosed by specialist physician. Patients with lung carcinoma (n=52) were divided in two categories male (n=29) and female (n=23) and both male and female groups were subdivided into four categories according to types of lung cancer and stage of disease. By types, they were subdivided into four groups: squamous cell carcinoma, adenocarcinoma, large cell carcinoma and small cell carcinoma. By stage male and female groups they were subdivided into four groups stageI, stageII, stageIII and stage IV., the result CCL18 of has shown significant increase (p<0.05) in squamous cell carcinoma than other types of lung cancer. In the current study serum levels of CCL18 shown in early stage is lower than in late stage in lung carcinoma patients